Chemours (CC) Pulls Back As Bullish Valuation Holds, Is The Stock Still Cheap?

Chemours (CC) stock has attracted renewed attention after recent trading moves and a shifting return profile, with the price closing at US$18.24 and performance varying sharply between the past month and past 3 months.

See our latest analysis for Chemours.

Chemours’ recent share price pullback, with a 30 day share price return of down 15% and a 90 day share price return of down 24.6%, contrasts with its year to date share price return of 48.9% and 1 year total shareholder return of 27.48%. This suggests that short term momentum has faded even as longer term holders still show a gain.

If Chemours’ swings have you thinking about where else capital could work, this is a good moment to look at 8 top copper producer stocks as another way to research materials exposure.

Bulls point to Chemours’ value score of 6 and a share price below the US$24.67 analyst target, while bears focus on the recent pullback and current loss. Which side does the valuation math lean toward next?

Most Popular Narrative: 39.2% Undervalued

Compared with Chemours’ last close at $18.24, the most followed narrative anchors on a fair value of $30, built on specific growth and profitability assumptions using a 9.52% discount rate.

The bullish analysts are assuming Chemours's revenue will grow by 7.4% annually over the next 3 years. The bullish analysts assume that profit margins will increase from 7.0% today to 19.5% in 3 years time.

Read the complete narrative.

There is a full growth roadmap behind that $30 figure. It combines faster top line expansion with a sharp margin reset and a future earnings multiple that undercuts the broader chemicals sector. Want to see which specific revenue and profit milestones this narrative is banking on, and how they stack against today’s loss making base?

Result: Fair Value of $30 (UNDERVALUED)

Have a read of the narrative in full and understand what's behind the forecasts.

However, Chemours still has meaningful overhangs, including ongoing PFAS and environmental litigation, as well as competitive pressure in TiO2 and refrigerants that could upset the bullish narrative.

Find out about the key risks to this Chemours narrative.

Next Steps

With Chemours pulled between optimism and concern, this is a good time to move quickly, review the full picture, and weigh both the upside and the risks for yourself. Start with the 4 key rewards and 2 important warning signs.

Looking for more Chemours-sized investment ideas?

If Chemours has sharpened your thinking about risk, reward, and timing, do not stop here. Use the Simply Wall Street Screener to pressure test fresh ideas.

• Target potential mispricings by scanning for companies with strong fundamentals that still trade for less than they might be worth using the 47 high quality undervalued stocks.
• Strengthen your income side by narrowing in on businesses with robust yields and balance sheets through the 7 dividend fortresses.
• Protect your downside by focusing on companies that pass strict quality and risk filters with the 82 resilient stocks with low risk scores.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com